Enhancing the profile of KRAS-mutant lung cancer
KRAS mutations constitute the largest subset of oncogene-driven lung adenocarcinomas, at approximately 30 %. Patients with KRAS-mutant metastatic lung cancer have heterogeneous clinical outcomes depending on the mutation subtype and associated co-mutations. El Osta et al. analysed the Lung Cancer Mutation Consortium (LCMC) database to evaluate the characteristics of these patients and the effect of KRAS mutation features on their outcomes . In all, data from 1,655 patients who consented to participate in LCMC between 2009 and 2015 were analysed for baseline characteristics, mutations status/ subtypes/co-mutations, OS (calculated from date of distant metastasis to death), and association of patient KRAS data with OS. Median follow-up was 2.15 years.